National AIDS Trust welcomes Scotland’s decision on long-acting injectable PrEP
Last Updated:Cabotegravir (CAB-LA) will help close the prevention gap for people who face barriers to adhering to oral PrEP.
Cabotegravir (CAB-LA) will help close the prevention gap for people who face barriers to adhering to oral PrEP.
Urgent action is now needed to expand access to testing and reach people not in care